Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a leader in synthetic DNA production, utilizing a proprietary semiconductor-based platform to drive innovations across biotechnology and healthcare. This page provides investors and industry professionals with timely, accurate updates on TWST's strategic developments and operational milestones.
Access consolidated press releases and news covering earnings announcements, product launches, research breakthroughs, and partnerships. Our curated updates ensure you stay informed about TWST's advancements in gene synthesis, high-throughput manufacturing, and applications in precision medicine.
Key content includes quarterly financial results, regulatory filings, technology patents, and collaborations with academic or industry partners. All materials are sourced directly from verified company communications to maintain factual integrity.
Bookmark this page for streamlined access to TWST's evolving role in synthetic biology. Check regularly for critical updates impacting market positioning and technological leadership in DNA synthesis.
Twist Bioscience (NASDAQ: TWST) has released its 2024 corporate responsibility report, highlighting its commitment to sustainability, social responsibility, and ethics. The company's silicon-based DNA manufacturing platform offers a more sustainable alternative to legacy methods, using 99.8% less reagents than 96-well plate approaches.
Key points:
- Twist's oligo manufacturing process for NGS target enrichment panels emits significantly less CO2 compared to industry standards
- The company disclosed its Scope 1 and Scope 2 emissions for the first time
- Twist prioritizes biosecurity, cybersecurity, and data protection
- The company fosters a diverse workforce, with 56% of U.S. employees identifying as individuals of color
- Twist invested over $220,000 in employee learning and development in fiscal 2023
Twist Bioscience (NASDAQ: TWST), a leading synthetic DNA provider, has announced its participation in the Baird Global Healthcare Conference 2024. Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present on Tuesday, September 10 at 2:35 p.m. Eastern Time in New York City.
The presentation will be webcast live and accessible through the company's investor relations website. A replay will be available for 30 days following the event. This conference appearance provides an opportunity for Twist Bioscience to showcase its silicon-based DNA synthesis platform and engage with healthcare industry professionals and investors.
Twist Bioscience (NASDAQ: TWST) has expanded its DNA synthesis offering with the launch of Gene Fragments ranging from 1.8kb to 5.0kb in length. This industry-leading product is available through Twist's ecommerce platform, offering the same speed, quality, and affordability as shorter fragments. Key features include:
- Turnaround time starting at two business days
- Low error rate of 1:7,500 base pairs
- Customizable with no order limit
- Universally compatible with various downstream cloning methods
The expanded offering aims to serve researchers at all stages, from Makers to Buyers, and is particularly beneficial for RNA therapeutic screening applications. Twist's CEO, Emily M. Leproust, Ph.D., emphasized the company's goal to push the boundaries of DNA synthesis and meet diverse customer needs.
Twist Bioscience (NASDAQ: TWST) has announced the granting of 94,200 restricted stock units (RSUs) to 30 newly hired employees as an inducement for their employment. This action was taken under Twist's Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, with 25% vesting on the one-year anniversary of the employee's start date and 1/16 vesting quarterly thereafter, contingent on continued employment. This plan is exclusively used for granting equity awards to new hires or those returning after a significant break in employment.
Twist Bioscience (Nasdaq: TWST) and bitBiome have announced a strategic collaboration, launching a joint Transaminase Enzyme Screening Kit. This kit contains 48 diverse transaminase enzymes for in-house screening and evaluation. The collaboration combines Twist's high-capacity DNA synthesis technology with bitBiome's proprietary database of over two billion microbe sequences.
The kit aims to provide labs and pharmaceutical companies with improved enzymes for biocatalysis, particularly for synthesizing active pharmaceutical ingredients (APIs). Transaminases are important in creating chiral amines, valuable building blocks for the pharmaceutical industry, offering a potential 'green alternative' to conventional synthesis methods.
This partnership leverages bitBiome's diverse sequence database and Twist's large-scale DNA synthesis capabilities to create innovative solutions for the biomanufacturing industry.
Twist Bioscience (NASDAQ: TWST) reported strong fiscal Q3 2024 results, with record revenue of $81.5 million, up 28% year-over-year. The company saw significant improvements in gross margin, reaching 43.3%, a 900 basis point increase from the previous year. Twist raised its FY 2024 revenue guidance to $310-$311 million and expects gross margin to be at the high end of the range at approximately 42%.
Key highlights include:
- SynBio revenue grew to $33.0 million
- NGS revenue increased to $43.4 million
- Biopharma revenue reached $5.1 million
- Shipped products to approximately 2,300 customers
- Launched new products including Multiplexed Gene Fragments and Express Antibodies
Despite the strong revenue growth, Twist reported a net loss of $85.6 million for the quarter, including a $45 million impairment related to Biopharma assets.
Twist Bioscience (NASDAQ: TWST) announced the first patient dosing in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405, a fully human IgG1 antibody discovered using Twist's synthetic antibody phage display libraries. The study aims to evaluate the pharmacodynamic activity of PBA-0405 in solid tumors, including head and neck squamous cell carcinoma, certain soft-tissue sarcomas, and triple-negative breast cancer.
PBA-0405 targets ROR1, a tumor-associated antigen, and is designed to make tumors visible to the immune system and induce an immune response. This marks the first antibody identified using Twist Biopharma Solutions' Library of Libraries to be tested in patients, validating the potential of their synthetic antibody libraries for discovering novel drug candidates for hard-to-treat cancers.
Twist Bioscience (NASDAQ: TWST) announced it will release its fiscal 2024 third quarter financial results on Friday, August 2, 2024, before market opening. The company will host a conference call and live audio webcast at 8:00 a.m. ET to discuss the results and provide business updates. The press release with financial results will be accessible on Twist Bioscience's website under the Investor Relations section. Interested participants can register on the company's website to receive the necessary dial-in information for the call. A webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) has expanded its high-throughput antibody portfolio with the launch of the CHO Express Antibodies, complementing their existing HEK293 antibodies. This expansion aims to support biopharma companies by providing customizable, cost-effective, and scalable antibody production solutions. CHO cell lines are pivotal in biotherapeutic drug manufacturing, and Twist's new service can deliver sequence-perfect IgG antibodies in as few as 13 business days. The antibodies range from 15 μg to 3,000 μg and include detailed yield data for screening. This development improves the efficiency and reduces the costs associated with antibody discovery and production.
Twist Bioscience (NASDAQ: TWST) has introduced a synthetic RNA control for H5N1 Influenza A, a key contributor to Highly Pathogenic Avian Influenza (HPAI). The new control covers 99.9% of the hemagglutinin (HA) and neuraminidase (NA) genome regions, facilitating enhanced research without the need for live viruses.
CEO Emily M. Leproust highlighted the importance of providing innovative tools for global monitoring and vaccine development. The synthetic control allows work to be undertaken in BSL-1 labs, speeding up research while maintaining high biosecurity standards.
This launch is part of Twist's broader portfolio of synthetic viral controls and research tools, aimed at supporting next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays. The company also offers products for other viral and respiratory diseases, including a comprehensive viral research panel for detecting H5N1 in wastewater.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
